Mackenzie Financial
MRNA icon

Mackenzie Financial’s Moderna MRNA Stock Holding History

Mackenzie Financial’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.14M Buy
116,245
+78,880
+211% +$4.08M 0.01% 703
2026
Q1 		$1.9M Buy
37,365
+25,598
+218% +$1.19M ﹤0.01% 936
2025
Q4 		$357K Buy
11,767
+566
+5% +$15.4K ﹤0.01% 1320
2025
Q3 		$289K Sell
11,201
-82
-0.7% -$2.29K ﹤0.01% 1427
2025
Q2 		$311K Sell
11,283
-20,158
-64% -$531K ﹤0.01% 1381
2025
Q1 		$891K Buy
31,441
+3,922
+14% +$139K ﹤0.01% 1013
2024
Q4 		$1.14M Sell
27,519
-2,687
-9% -$128K ﹤0.01% 911
2024
Q3 		$2.02M Sell
30,206
-17,432
-37% -$1.6M ﹤0.01% 719
2024
Q2 		$5.66M Sell
47,638
-4,005
-8% -$507K 0.01% 522
2024
Q1 		$5.5M Sell
51,643
-63,364
-55% -$6.39M 0.01% 539
2023
Q4 		$11.4M Buy
115,007
+46,964
+69% +$3.95M 0.02% 415
2023
Q3 		$7.01M Buy
68,043
+2,135
+3% +$238K 0.01% 484
2023
Q2 		$8.02M Buy
65,908
+938
+1% +$125K 0.01% 483
2023
Q1 		$9.98M Sell
64,970
-19,259
-23% -$3.18M 0.02% 446
2022
Q4 		$15.1M Sell
84,229
-7,034
-8% -$1.15M 0.03% 346
2022
Q3 		$10.8M Sell
91,263
-4,676
-5% -$710K 0.02% 398
2022
Q2 		$13.7M Buy
95,939
+3,063
+3% +$438K 0.02% 387
2022
Q1 		$16M Buy
92,876
+25,299
+37% +$4.26M 0.02% 397
2021
Q4 		$17.2M Sell
67,577
-299
-0.4% -$87.4K 0.02% 391
2021
Q3 		$26.1M Buy
67,876
+352
+0.5% +$130K 0.04% 305
2021
Q2 		$15.9M Buy
67,524
+4,141
+7% +$740K 0.02% 373
2021
Q1 		$8.3M Buy
63,383
+11,198
+21% +$1.62M 0.01% 447
2020
Q4 		$5.45M Sell
52,185
-11,589
-18% -$1.17M 0.01% 432
2020
Q3 		$4.51M Buy
63,774
+12,033
+23% +$839K 0.01% 416
2020
Q2 		$3.32M Buy
+51,741
New +$2.83M 0.01% 459

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Mackenzie Financial's MRNA Position: Q2 2026 in Review

Mackenzie Financial increased its Moderna (MRNA) stake by 211% in Q2 2026, buying an estimated $4.08M and bringing the position to 116,245 shares worth $8.14M. The position accounts for 0.01% of the portfolio, ranked #703.

Mackenzie Financial first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $26.1M in Q3 2021. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Mackenzie Financial held 116,245 shares of Moderna worth $8.14M as of Q2 2026.
  • Mackenzie Financial bought 78,880 Moderna shares in Q2 2026, an estimated $4.08M.
  • Moderna made up 0.01% of Mackenzie Financial's portfolio in Q2 2026, its #703 holding.
  • Mackenzie Financial first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Mackenzie Financial's Moderna position peaked at $26.1M in Q3 2021.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.